Drugs / TT-173
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01595360 | Apr 2012 → Sep 2013 | — | Thrombotargets Europe S.L | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02012569 | Nov 2013 → Jul 2015 | — | Thrombotargets Europe S.L | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02687399 | Jan 2016 → Sep 2018 | osteoarthritis, knee | Thrombotargets Europe S.L | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-173 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01595360 ↗ |
| Route | Topical | “It is applied directly to the bleeding site after tooth extraction” NCT01595360 ↗ |